(Sharecast News) – Syncona shares fell as the UK healthcare investment firm said Novartis had stopped the development of experimental eye treatment, GT005, resulting in milestone payments write-off of £54.5m for Gyroscope Holdings in which Syncona once held a 54% stake.
Gyroscope was sold to Novartis in February last year in $1.5bn deal, with Syncona receiving $442m (£326m) for its stake.
UP Global Sourcing opens new Paris showroom
(Sharecast News) - UP Global Sourcing announced the opening of a new showroom in Paris on Monday as part of its drive into the continental European market. The London-listed company, which trades as Ultimate Products and oversees a brand portfolio including Salter and...